What is Novocuff?
Novocuff, Inc. is a medical device company focused on enhancing pregnancy outcomes by addressing critical issues such as preterm births stemming from PPROM (preterm premature rupture of membranes) and cervical shortening. The company's innovative solutions are designed to provide crucial support during pregnancy, aiming to reduce adverse outcomes and improve maternal and infant health. This enterprise-level funding positions Novocuff to accelerate the development and deployment of its technology in a market with significant unmet needs.
How much funding has Novocuff raised?
Novocuff has raised a total of $52M across 2 funding rounds:
Series A
$26M
Series A
$26M
Series A (2024): $26M with participation from Avestria Ventures Management, RH Capital, and AXA IM ALTS - Real Assets
Series A (2024): $26M led by RH Capital, AXA IM ALTS - Real Assets, and Avestria Ventures Management
Key Investors in Novocuff
Avestria Ventures Management
Avestria Ventures Management is a venture capital firm specializing in early-stage women's health and life science companies, particularly those led by women. They aim to address underfunding in this sector by supporting businesses that enhance healthcare quality and access through technology and data.
RH Capital
RH Capital operates within the Venture Capital & Private Equity industry, focusing on investments that drive innovation and growth in its portfolio companies.
AXA IM ALTS - Real Assets
AXA IM Alts is an alternative investment specialist focused on generating long-term, sustainable value across real estate, infrastructure, and credit, with a commitment to sustainability and net-zero emissions.
What's next for Novocuff?
With the recent influx of capital, Novocuff is poised for substantial growth and market penetration. The Series A financing, characterized as a major strategic investment, will likely fuel advancements in product development, clinical trials, and commercialization efforts. The company's focus on improving pregnancy outcomes aligns with growing global healthcare priorities, suggesting a strong trajectory for future expansion and potential follow-on funding rounds as it scales its impact in women's health.
See full Novocuff company page
